Gulf Pharmaceutical Industries P.S.C Reports Second Quarter 2024 Earnings

Gulf Pharmaceutical Industries P.S.C (ADX:JULPHAR) Second Quarter 2024 Results

Key Financial Results

• Revenue: د.إ444.0m (up 9.5% from 2Q 2023).
• Net loss: د.إ2.50m (loss narrowed by 94% from 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Gulf Pharmaceutical Industries P.S.C Earnings Insights

Looking ahead, revenue is forecast to grow 5.4% p.a. on average during the next 2 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in Asia.

Performance of the market in United Arab Emirates.

The company's shares are up 9.4% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Gulf Pharmaceutical Industries P.S.C's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.